A detailed history of High Tower Advisors, LLC transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 305,814 shares of ACRS stock, worth $886,860. This represents 0.0% of its overall portfolio holdings.

Number of Shares
305,814
Previous 312,714 2.21%
Holding current value
$886,860
Previous $343,000 0.58%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.12 - $1.4 $7,728 - $9,660
-6,900 Reduced 2.21%
305,814 $345,000
Q2 2024

Aug 13, 2024

BUY
$1.01 - $1.36 $101 - $136
100 Added 0.03%
312,714 $343,000
Q1 2024

May 06, 2024

SELL
$0.92 - $1.44 $27,977 - $43,790
-30,410 Reduced 8.87%
312,614 $387,000
Q4 2023

Feb 12, 2024

SELL
$0.64 - $6.49 $17,137 - $173,789
-26,778 Reduced 7.24%
343,024 $360,000
Q3 2023

Nov 08, 2023

SELL
$6.56 - $10.95 $65,600 - $109,500
-10,000 Reduced 2.63%
369,802 $2.53 Million
Q2 2023

Aug 14, 2023

BUY
$7.89 - $10.64 $1.48 Million - $1.99 Million
187,479 Added 97.48%
379,802 $3.94 Million
Q1 2023

May 11, 2023

SELL
$7.07 - $17.95 $714 - $1,812
-101 Reduced 0.05%
192,323 $1.56 Million
Q4 2022

Feb 08, 2023

BUY
$14.33 - $18.37 $1.92 Million - $2.46 Million
134,071 Added 229.76%
192,424 $3.03 Million
Q3 2022

Nov 09, 2022

SELL
$13.07 - $18.22 $22,728 - $31,684
-1,739 Reduced 2.89%
58,353 $919,000
Q2 2022

Aug 10, 2022

SELL
$10.16 - $17.08 $32,583 - $54,775
-3,207 Reduced 5.07%
60,092 $840,000
Q1 2022

May 12, 2022

SELL
$9.74 - $17.92 $44,609 - $82,073
-4,580 Reduced 6.75%
63,299 $1.09 Million
Q4 2021

Feb 10, 2022

SELL
$12.27 - $18.49 $4,895 - $7,377
-399 Reduced 0.58%
67,879 $987,000
Q3 2021

Nov 12, 2021

BUY
$13.38 - $18.8 $50,844 - $71,440
3,800 Added 5.89%
68,278 $1.23 Million
Q1 2021

May 10, 2021

BUY
$5.86 - $27.73 $40,891 - $193,499
6,978 Added 12.14%
64,478 $1.62 Million
Q4 2020

Feb 10, 2021

SELL
$2.65 - $7.61 $5,790 - $16,627
-2,185 Reduced 3.66%
57,500 $373,000
Q3 2020

Nov 13, 2020

SELL
$1.5 - $2.71 $14,925 - $26,964
-9,950 Reduced 14.29%
59,685 $153,000
Q1 2020

May 21, 2020

BUY
$0.75 - $2.18 $7,500 - $21,800
10,000 Added 16.77%
69,635 $72,000
Q3 2019

Nov 12, 2019

BUY
$0.79 - $2.47 $443 - $1,388
562 Added 0.95%
59,635 $65,000
Q2 2019

Aug 13, 2019

SELL
$2.13 - $7.06 $276 - $917
-130 Reduced 0.22%
59,073 $130,000
Q1 2019

May 15, 2019

SELL
$5.63 - $7.84 $57,442 - $79,991
-10,203 Reduced 14.7%
59,203 $355,000
Q4 2018

Feb 14, 2019

SELL
$6.3 - $15.4 $34,196 - $83,591
-5,428 Reduced 7.25%
69,406 $512,000
Q3 2018

Nov 09, 2018

BUY
$14.38 - $20.89 $129,678 - $188,386
9,018 Added 13.7%
74,834 $1.09 Million
Q2 2018

Aug 14, 2018

SELL
$16.46 - $20.33 $197,520 - $243,959
-12,000 Reduced 15.42%
65,816 $1.32 Million
Q1 2018

May 15, 2018

SELL
$17.08 - $25.64 $884,743 - $1.33 Million
-51,800 Reduced 39.96%
77,816 $1.36 Million
Q4 2017

Feb 14, 2018

SELL
$21.47 - $27.8 $312,238 - $404,295
-14,543 Reduced 10.09%
129,616 $3.2 Million
Q3 2017

Nov 14, 2017

BUY
$23.02 - $28.8 $4,604 - $5,760
200 Added 0.14%
144,159 $3.72 Million
Q2 2017

Aug 14, 2017

BUY
N/A
143,959
143,959 $3.9 Million

Others Institutions Holding ACRS

About Aclaris Therapeutics, Inc.


  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $193M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.